Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafoxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against *Mycobacterium tuberculosis* and *Mycobacterium avium* Complex

Haruaki Tomioka, Katsumasa Sato, Tatsuya Akaki, Hiroko Kajitani, Shin Kawahara and Mitsunori Sakatani

Updated information and services can be found at:
http://aac.asm.org/content/43/12/3001

**REFERENCES**

These include:

This article cites 25 articles, 20 of which can be accessed free at:  http://aac.asm.org/content/43/12/3001#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article),  more»

Information about commercial reprint orders:  http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to to another ASM Journal go to:  http://journals.asm.org/site/subscriptions/
Comparative In Vitro Antimicrobial Activities of the Newly Synthesized Quinolone HSR-903, Sitafloxacin (DU-6859a), Gatifloxacin (AM-1155), and Levofloxacin against *Mycobacterium tuberculosis* and *Mycobacterium avium* Complex

HARUAKI TOMIOKA,1* KATSUMASA SATO,1 TATSUYA AKAKI,1,2 HIROKO KAJITANI,1 SHIN KAWAHARA,3 AND MITSUNORI SAKATANI4

Department of Microbiology and Immunology1 and Department of Dermatology,2 Shimane Medical University, Izumo, Shimane 693-8501, National Sanatorium Minami-Okayama Hospital, Okayama 710-0304,3 and National Sanatorium Kinki-Chuo Hospital, Osaka 591-8555,4 Japan

Received 9 April 1999/Returned for modification 13 August 1999/Accepted 28 September 1999

We compared the in vitro antimycobacterial activity of a new fluoroquinolone, HSR-903, with strong activity against gram-positive cocci with those of levofloxacin (LVFX), sitafloxacin (STFX), and gatifloxacin (GFLX). The MICs of the quinolones for *Mycobacterium tuberculosis* and *Mycobacterium avium* complex were in the order STFX < GFLX < LVFX < HSR-903 and STFX < GFLX < HSR-903 < LVFX, respectively. HSR-903 effectively eliminated intramacrophagal *M. tuberculosis*, as did LVFX, and exhibited bacteriostatic effects against *M. tuberculosis* replicating in type II alveolar cells.

The recent increase in AIDS-associated intractable mycobacterial infections, including multidrug-resistant tuberculosis (MDR-TB) and disseminated *Mycobacterium avium* complex (MAC) infections, has caused serious problems around the world (4, 7, 28). New quinolones are recommended for use as second-choice drugs in treatment of MDR-TB, since they have potent anti-*Mycobacterium tuberculosis* activity and good pharmacokinetics, in terms of tissue and cellular distribution, and have few adverse effects (1, 5, 6). Ciprofloxacin (CPFX), ofloxacin (OFLX),sparfloxacin (SPFX), and levofloxacin (LVFX) have good therapeutic efficacies against experimental *M. tuberculosis* infection in mice (9, 11) and are efficacious in clinical control of tuberculosis, including MDR-TB, when given in combination with other antituberculous drugs (1, 26).

HSR-903, a new fluoroquinolone [(S)-(−)-5-amino-7-(7-amino-5-azaspiro [2,4]hept-5-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid methanesulfonate], has a broad spectrum of action against both gram-positive and gram-negative bacteria. HSR-903 has more potent activity against *Staphylococcus aureus*, including methicillin-resistant *S. aureus*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Helicobacter pylori* than do other fluoroquinolones, including CPFX, SPFX, and LVFX (20, 24, 27). In pharmacological studies with mice, the levels of HSR-903 in the lungs were much higher than those in the plasma after oral administration, and concentrations of HSR-903 in lung were higher than those of CPFX and LVFX (13). In humans, the maximum concentration of drug in serum (Cmax) of HSR-903 at 200 mg/kg of body weight was 0.86 μg/ml at 1.3 to 2.4 h (time to Cmax [Tmax]), and the half-life (T1/2) and area under the concentration-time curve from 0 to 24 h (AUC0–24) of HSR-903 were 18.0 h and 12.8 μg · h/ml, respectively (13a, 23). HSR-903 also exhibited potent therapeutic efficacy against experimental murine infections caused by penicillin-resistant *S. pneumoniae* and *H. influenzae* (27). In the present study, the in vitro antimicrobial activity of HSR-903 against *M. tuberculosis* and MAC was compared with those of several other fluoroquinolones, including LVFX, sitafloxacin (STFX; DU-6859a), and gatifloxacin (GFLX; AM-1155), which possess potent in vitro and in vivo antimycobacterial activities (9, 11, 14–18, 21).

*M. tuberculosis* (45 strains), *avium* (20 strains), and *Mycobacterium intracellulare* (20 strains) were isolated from sputum specimens of non-human immunodeficiency virus-infected patients with sporadic tuberculosis or MAC infection in several hospitals in Japan and grown in 7H9 medium. Each strain was isolated from a different patient. The *M. tuberculosis* isolates were divided into MDR *M. tuberculosis* with resistance to both rifampin (RMP) and isoniazid (INH) (MIC RMP of ≤0.15 μg/ml and MIC INH of ≤0.4 μg/ml) and non-MDR *M. tuberculosis* (MIC RMP of ≤0.78 μg/ml and MIC INH of ≤0.2 μg/ml) strains, according to the criteria of the Centers for Disease Control and Prevention (10). Alternatively, the *M. tuberculosis* isolates were divided into LVFX-susceptible (MICLVFX of ≤0.78 μg/ml) and LVFX-resistant (MICLVFX of ≥1.56 μg/ml) strains (17).

In this study, the activities of the following drugs were measured: HSR-903 (Hokuriku Pharmaceutical Co., Fukui, Japan), LVFX (Daiichi Pharmaceutical Co., Tokyo, Japan), STFX (Daiichi Pharmaceutical Co.), GFLX (Kyorin Pharmaceutical Co., Tokyo), RMP (Taiho Pharmaceutical Co.), clarithromycin (CAM) (Taisho Pharmaceutical Co., Tokyo), and INH (Taiho Pharmaceutical Co.). MICs of test drugs were determined as previously reported (18) by either the agar dilution method with Middlebrook 7H11 medium (Difco Laboratories, Detroit, Mich.) or the broth dilution method in microculture wells with 7H9S medium as described by Yajuko et al. (25).

The activities of test drugs against intracellular *M. tuberculosis* were measured as follows. The Mono Mac 6 human macrophage (Mφ)-like cell line (MM-6Mφs; German Collection of Microorganisms and Cell Cultures, Mascheroder, Germany)
and A-549 human type II lung epithelial cell line (A-549 cells; American Type Culture Collection, Rockville, Md.) were used as host cells for *M. tuberculosis* infection. Cultured MM6-Mδs and A-549 cells (4 × 10^6 cells) suspended in RPMI 1640 medium and Ham’s F-12K medium containing 5% fetal bovine serum (FBS) (BioWhittaker Co., Walkersville, Md.), respectively, were seeded on round-bottom microculture plates. The resulting cells were then infected with *M. tuberculosis* “Kurono” [MIC<sub>RMP(7H11)</sub> of ≤0.05 μg/ml or MIC<sub>INO(7H11)</sub> of ≤0.05 μg/ml] at a multiplicity of infection (MOI) of 30 for 3 h and an MOI of 10 for 2 h, respectively. (These conditions yielded comparable loads of mycobacterial infection for MM6-Mδs and A-549 cells.) After being washed with 2% FBS–Hanks’ balanced salt solution, *M. tuberculosis*-infected cells were cultured in corresponding medium (0.2 ml) containing 1% FBS in the presence or absence of test drugs for up to 7 days. At intervals, the cells were lysed with 0.07% sodium dodecyl sulfate and washed with distilled water by centrifugation, and the number of recovered CFU was counted on 7H11 agar plates.

Table 1 summarizes the MICs at which 50 and 90% of the test strains were inhibited (MIC<sub>50</sub> and MIC<sub>90</sub>, respectively) of HSR-903, STFX, GFLX, LVFX, RMP, INH, and CAM for *M. tuberculosis* and MAC. The MIC<sub>50</sub> and MIC<sub>90</sub> of test quinolones were distributed over a range from 0.1 to 0.78 μg/ml and 0.39 to 25 μg/ml for non-MDR *M. tuberculosis* and MDR *M. tuberculosis* strains, respectively. Their MICs were in the range for non-MDR MAC strains, but markedly increased in the case of MDR-M. *M. tuberculosis* strains. The MICs of CAM were high for both non-MDR *M. tuberculosis* and MDR-M. *M. tuberculosis* strains.

Notably, the MICs of test quinolones for MDR-M. *M. tuberculosis* isolates were 4 to 32 times higher than those of MICs for non-MDR-M. *M. tuberculosis* strains. This finding is not surprising, since in the present study, most MDR-M. *M. tuberculosis* strains with increased quinolone resistance were isolated from patients who had been treated with antituberculous regimens containing fluoroquinolones, such as OFLX and CPFX. Moreover, certain MDR-M. *M. tuberculosis* isolates with susceptibility to quinolones as high as those of non-MDR-M. *M. tuberculosis* strains were isolated from patients who had never undergone quinolone treatment. Indeed, it was previously reported that MICs of these quinolones were not increased in MDR-*M. tuberculosis* isolates (8). Similarly, the MICs of HSR-903, STFX, and GFLX for LVFX-resistant *M. tuberculosis* strains (MIC<sub>LVFX</sub> of ≥1.56 μg/ml) were 8 to 32 times higher than those for LVFX-susceptible *M. tuberculosis* strains (MIC<sub>LVFX</sub> of ≤0.78 μg/ml).

The MIC<sub>50</sub> and MIC<sub>90</sub> of test quinolones for *M. avium* were distributed over a range from 1.56 to 25 μg/ml and in the order STFX ≤ GFLX < HSR-903 = LVFX. Their MICs for *M. intracellularle* were distributed from 6.25 to 25 μg/ml and in the order STFX ≤ GFLX ≤ HSR-903 < LVFX. Thus, the activities of these quinolones against MAC can be ranked as STFX ≤ GFLX ≤ HSR-903 ≤ LVFX. The activities of both HSR-903 and LVFX are poor against MAC. Notably, the MIC<sub>50</sub> of the quinolones for *M. avium* tended to be lower than those for *M. intracellularle*, as previously reported (22). In contrast, the MICs of RMP and CAM for *M. avium* were higher than those for *M. intracellularle*.

Next, we examined the antimicrobial activity of HSR-903 against intracellular *M. tuberculosis*. Figure 1 shows the effects of HSR-903 and LVFX on the mode of intracellular growth of *M. tuberculosis* “Kurono” residing in MM6-Mδs and A-549 cells, when these drugs were added to the culture medium at the C<sub>max</sub> in blood (0.86 and 2.0 μg/ml, respectively) (3, 23). The *M. tuberculosis* bacteria in MM6-Mδs were progressively killed in similar fashions by HSR-903 and LVFX during a 7-day cultivation. While gradual but progressive killing by LVFX was noted for *M. tuberculosis* bacteria residing in A-549 cells, HSR-903-mediated bacterial elimination was somewhat incomplete for the organisms residing in A-549 cells. In separate experiments, when these drugs were added at the MIC (7HSF medium) (0.25 μg/ml each for HSR-903 and LVFX), HSR-903 displayed bacteriostatic activity against the organisms residing in MM6-Mδs, while LVFX did not (data not shown). In the case of A-549 cells, only weak bacteriostatic effects were observed for the two quinolones against intracellular *M. tuberculosis* (data not shown).

In this study, we compared the in vitro activity of a newly synthesized fluoroquinolone, HSR-903, with those of LVFX, STFX, and GFLX as reference drugs. First, the MICs of HSR-903 for *M. tuberculosis* isolates were the same as or twice as high as those of LVFX. HSR-903 exhibited a broader MIC distribution for MDR *M. tuberculosis* isolates than did LVFX, with a peak around 3.13 μg/ml, the same as that of LVFX (data not shown). It thus appears that HSR-903 has somewhat weak-

### Table 1. MICs of HSR-903, STFX, GFLX, LVFX, RMP, INH, and CAM for *M. tuberculosis* and MAC strains

<table>
<thead>
<tr>
<th>Strains</th>
<th>No. of strains</th>
<th>MIC&lt;sub&gt;50&lt;/sub&gt; (μg/ml)</th>
<th>MIC&lt;sub&gt;90&lt;/sub&gt; (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HSR-903</td>
<td>STFX</td>
<td>GFLX</td>
</tr>
<tr>
<td><em>M. tuberculosis</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-MDR&lt;sup&gt;a&lt;/sup&gt;</td>
<td>23</td>
<td>0.78</td>
<td>0.1</td>
</tr>
<tr>
<td>MDR&lt;sup&gt;a&lt;/sup&gt;</td>
<td>22</td>
<td>3.13</td>
<td>0.39</td>
</tr>
<tr>
<td>LVFX-S&lt;sup&gt;a&lt;/sup&gt;</td>
<td>27</td>
<td>0.78</td>
<td>0.1</td>
</tr>
<tr>
<td>LVFX-R&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18</td>
<td>6.25</td>
<td>0.78</td>
</tr>
<tr>
<td><em>M. avium</em></td>
<td>20</td>
<td>6.25</td>
<td>1.56</td>
</tr>
<tr>
<td><em>M. intracellularle</em></td>
<td>20</td>
<td>12.5</td>
<td>25</td>
</tr>
</tbody>
</table>

<sup>a</sup> MICs were determined by the agar dilution method with 7H11 medium.
<sup>b</sup> Either MIC<sub>RMP</sub> or MIC<sub>INO</sub> of ≤0.78 μg/ml or MIC<sub>LVFX</sub> of ≤0.2 μg/ml.
<sup>c</sup> MIC<sub>RMP(7H11)</sub> of ≥1.56 μg/ml and MIC<sub>INO(7H11)</sub> of ≥0.4 μg/ml.
<sup>d</sup> LVFX-S, LVFX susceptible (MIC<sub>LVFX</sub> of ≤0.78 μg/ml).
<sup>e</sup> LVFX-R, LVFX resistant (MIC<sub>LVFX</sub> of ≥1.56 μg/ml).
We thank Hokuriku Pharmaceutical Co., Daiichi Pharmaceutical Co., Kyorin Pharmaceutical Co., and Taisho Pharmaceutical Co. for providing HSR-903, STFX and LVFX, GFLX, and CAM, respectively.

REFERENCES


